Designing an immuno-epitope candidate vaccine from (Opa, ProA, ProB, RmpM and BamD) proteins against Neisseria gonorrhoeae and Neisseria meningitides

Q3 Medicine

Vacunas Pub Date : 2024-10-01 DOI:10.1016/j.vacun.2024.07.004

{"title":"Designing an immuno-epitope candidate vaccine from (Opa, ProA, ProB, RmpM and BamD) proteins against Neisseria gonorrhoeae and Neisseria meningitides","authors":"","doi":"10.1016/j.vacun.2024.07.004","DOIUrl":null,"url":null,"abstract":"<div><div>The development of a conventional vaccine against gonococci has been difficult since there are no precise correlates of immune protection and the mechanisms of protective immunity are not yet understood. However, the drop in gonorrhea infections might be attributed to the development of vaccines based on <em>Neisseria meningitidis</em>' outer membrane. The goal of this research was to develop a multi-epitope vaccination utilizing proteins from <em>N. meningitidis</em> and <em>Neisseria gonorrhoeae</em>. A <em>Neisseria</em> Multi-Epitope Vaccine (NMEV), containing Opa, ProA, ProB, RmpM, and BamD, was developed using immunophysicochemical informatics techniques. The vaccine consists of 297 amino acids. Antigenicity and sensitivity to NMEV were evaluated. NMEV generates a substantial amount of immune cells and cytokines. The total quality factor of the NMEV 2D structure is around 91%. The vaccine's safety, effectiveness, and other properties make it an attractive option for in vitro and in vivo testing. The suggested NMEV subunit vaccine has the potential to elicit a strong immune response, necessitating additional in vitro and in vivo studies to eliminate Neisseria infections.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988724000736","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The development of a conventional vaccine against gonococci has been difficult since there are no precise correlates of immune protection and the mechanisms of protective immunity are not yet understood. However, the drop in gonorrhea infections might be attributed to the development of vaccines based on Neisseria meningitidis' outer membrane. The goal of this research was to develop a multi-epitope vaccination utilizing proteins from N. meningitidis and Neisseria gonorrhoeae. A Neisseria Multi-Epitope Vaccine (NMEV), containing Opa, ProA, ProB, RmpM, and BamD, was developed using immunophysicochemical informatics techniques. The vaccine consists of 297 amino acids. Antigenicity and sensitivity to NMEV were evaluated. NMEV generates a substantial amount of immune cells and cytokines. The total quality factor of the NMEV 2D structure is around 91%. The vaccine's safety, effectiveness, and other properties make it an attractive option for in vitro and in vivo testing. The suggested NMEV subunit vaccine has the potential to elicit a strong immune response, necessitating additional in vitro and in vivo studies to eliminate Neisseria infections.

查看原文本刊更多论文

利用（Opa、ProA、ProB、RmpM 和 BamD）蛋白设计针对淋病奈瑟菌和脑膜炎奈瑟菌的免疫表位候选疫苗

由于没有精确的免疫保护相关因素，保护性免疫的机制也尚未被了解，因此很难开发出针对淋球菌的常规疫苗。不过，淋病感染率的下降可能要归功于基于奈瑟氏脑膜炎球菌外膜的疫苗的开发。这项研究的目标是利用脑膜炎奈瑟菌和淋病奈瑟菌的蛋白质开发一种多表位疫苗。利用免疫物理化学信息学技术开发了一种奈瑟菌多表位疫苗（NMEV），其中包含 Opa、ProA、ProB、RmpM 和 BamD。该疫苗由 297 个氨基酸组成。对 NMEV 的抗原性和敏感性进行了评估。NMEV 产生了大量的免疫细胞和细胞因子。NMEV 二维结构的总质量因子约为 91%。该疫苗的安全性、有效性和其他特性使其成为体外和体内测试的一个有吸引力的选择。建议的 NMEV 亚单位疫苗有可能引起强烈的免疫反应，因此有必要进行更多的体外和体内研究，以消除奈瑟氏菌感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vacunas Medicine-Infectious Diseases

CiteScore

3.90

自引率

0.00%

发文量

138

审稿时长

62 days

期刊介绍： Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.